For the second quarter of the fiscal year ending December 2026, consolidated results show net sales of 5.02 billion yen, operating loss of 3.236 billion yen, and net loss attributable to owners of the parent of 2.714 billion yen for the interim period. The full-year forecast remains unchanged at net sales of 13.30 billion yen and operating loss of 1.023 billion yen, among others. The capital structure shows net assets of 205 million yen and equity ratio of 3.5%. R&D expenses are set to rise sharply to 2.67 billion yen, with attention on progress in HGF gene therapy-related development and related partnerships and fundraising developments.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4563","jir_company_name":"Anges Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4563-20260814-03.pdf","jir_short_summary":"For the second quarter of the fiscal year ending December 2026, consolidated results show net sales of 5.02 billion yen, operating loss of 3.236 billion yen, and net loss attributable to owners of the parent of 2.714 billion yen for the interim period. The full-year forecast remains unchanged at net sales of 13.30 billion yen and operating loss of 1.023 billion yen, among others. The capital structure shows net assets of 205 million yen and equity ratio of 3.5%. R&D expenses are set to rise sharply to 2.67 billion yen, with attention on progress in HGF gene therapy-related development and related partnerships and fundraising developments.","jir_summary":"### Overview of Results\nDuring this interim period, while business revenue increased year over year, operating losses widened due to a substantial rise in R&D spending and some reduction in selling, general and administrative expenses. Expenditures related to manufacturing testing and preparation for applications in relation to HGF gene therapy contributed to the increase. The full-year outlook remains unchanged, but liquidity management remains a focal point.\n\n### Financial Position and Fundraising\nTotal assets of 3,660 million yen, net assets of 2.05 hundred million yen, and equity ratio of 3.5% indicate a low level. Cash and deposits declined to 281 million yen. The company continues capital policy moves such as the 46th share subscription rights and redemption of private placement bonds, and is considering additional fundraising to strengthen liquidity. Important later events include planned exercise and cancellation of stock acquisition rights, redemption of private placement bonds, and fundraising via third-party allottees.","jir_financial_highlights":"Net Sales: 502\u767e\u4e07\u5186 (YoY 21.2% increase)\nOperating Loss: \u25b33,236\u767e\u4e07\u5186 (YoY \u25b32,400\u767e\u4e07\u5186)\nOrdinary Loss: \u25b32,560\u767e\u4e07\u5186 (YoY \u25b33,898\u767e\u4e07\u5186)\nNet Loss Attributable to Owners of Parent: \u25b32,714\u767e\u4e07\u5186 (YoY \u25b33,966\u767e\u4e07\u5186)\nTotal Assets: 3,660\u767e\u4e07\u5186 (Decrease from end of prior period)","jir_category":"","jir_hashtags":"#AngesCo.,Ltd., #FinancialResults, #CapitalPolicy","jir_key_figures":"Net Sales: 502\u767e\u4e07\u5186 (YoY +21.2%)\nOperating Loss: \u25b33,236\u767e\u4e07\u5186\nOrdinary Loss: \u25b32,560\u767e\u4e07\u5186\nInterim Net Loss: \u25b32,714\u767e\u4e07\u5186","jir_meta_title":"\u3010Anges Co., Ltd.\u3011Q2 FY2026 Interim Financial Results \u2014 Net Sales 5.02 billion yen, Losses Widen","jir_meta_description":"Summary of Anges Co., Ltd.'s Q2 FY2026 interim financial results. Net sales were 502 million yen, operating loss 3,236 million yen, full-year forecast unchanged. Focus on R&D spending related to HGF gene therapy and fundraising trends.","jir_og_title":"\u3010Anges Co., Ltd.\u3011Q2 FY2026 Interim Financial Results \u2014 Net Sales 5.02 billion yen, Losses Widen","jir_og_description":"Anges' interim results show year-over-year revenue improvement but challenges from increased R&D spending and liquidity concerns. Attention on future fundraising trends.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57619,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-104437","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n